Skip to content
Homepage
Author:
Xenetic Biosciences, Inc.
Posted Date:
June 4, 2026
Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma
Xenetic Biosciences, Inc.
June 4, 2026
Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
Xenetic Biosciences, Inc.
June 1, 2026
Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Xenetic Biosciences, Inc.
May 13, 2026
Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting
Xenetic Biosciences, Inc.
April 22, 2026
Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results
Xenetic Biosciences, Inc.
March 13, 2026
